Sign in

Lauren Young

Director at CCCS
Board

About Lauren Young

Lauren Young, age 42, is a Class II independent director of CCC Intelligent Solutions Holdings Inc. (CCCS), serving since July 30, 2021 with a current term expiring at the fiscal year 2026 annual meeting. She is a Managing Director at Advent International and holds a bachelor’s degree from Davidson College and an MBA from Harvard Business School .

Past Roles

OrganizationRoleTenureCommittees/Impact
Advent International, L.P.Managing Director (joined firm in 2011)2011–presentPrivate equity leadership and board oversight across technology/financial sectors
The Carlyle GroupU.S. Buyout Fund team member2006–2009Investment execution in large-cap buyouts
McColl PartnersAnalyst2004–2006Sell-side and buy-side transaction analysis

External Roles

OrganizationRolePublic/PrivateNotes
Definitive HealthcareDirectorPublicCurrent board service
Iodine SoftwareDirectorPrivateCurrent board service

Board Governance

  • Board and committee activity in FY2024: Board met 8 times; Audit 7; Nominating & Corporate Governance (NCGC) 3; Human Capital & Compensation (HCCC) 5 .
  • Attendance: In FY2024, each director other than Christopher Egan attended at least 75% of Board and committee meetings during their tenure (implies Ms. Young met or exceeded 75%) .
  • Committee memberships: NCGC member (Chair: Eric Wei; members: Teri Williams, Lauren Young). All NCGC members are independent under Nasdaq/SEC rules .
  • Not on Audit or HCCC per the committee rosters .
  • Independence: Company states seven independent directors and confirms committee independence; Ms. Young is treated as independent under Nasdaq/SEC standards .
  • Board leadership: CEO also Chair; a “presiding director” ensures independent leadership—currently Eric Wei (an Advent designee) .

Fixed Compensation

ComponentAmountTerms
Annual cash retainer$0Company pays $15,000 quarterly retainer to eligible non-employee directors; CCC does not compensate directors employed by CCC or by the Advent Investor/affiliates (Ms. Young receives no cash fees) .
Committee chair fee$0$25,000 RSU chair grant applies to eligible chairs; not paid to Advent-affiliated directors .
Meeting fees$0Not disclosed/none in policy; directors compensated via retainers/annual grants only .
Annual equity RSU grant$0$250,000 RSU grant to eligible directors; not granted to Advent-affiliated directors (Ms. Young had no 2024 director stock awards) .

Performance Compensation

MetricDesignPayout
N/A for Ms. YoungCCC director pay is retainers and time-vested RSUs (no performance metrics); Advent-affiliated directors (including Ms. Young) receive no cash or equity director compensation .

Other Directorships & Interlocks

  • Advent Investor designation rights: Shareholder Rights Agreement grants Advent the right to designate directors and to have at least one Advent-nominated director on each Board committee while Advent maintains specified ownership thresholds; Ms. Young is an Advent-designated director .
  • CCC repurchased 7 million shares from Advent on March 3, 2025 at $10.325 per share ($72.3M); terms were reviewed and approved by CCC’s independent Audit Committee. This is a related-party transaction with a >5% holder processed through independent oversight .

Expertise & Qualifications

  • Finance and investing expertise from Advent/Carlyle; board experience in technology and healthcare software (Definitive Healthcare, Iodine Software) .
  • Academic credentials: Davidson College (BA), Harvard Business School (MBA) .

Equity Ownership

HolderShares Beneficially Owned% of OutstandingNotes
Lauren YoungNo personal beneficial ownership reported as of April 1, 2025 .
Advent Investor (affiliates)97,342,52614.77%Major shareholder; Ms. Young is an Advent MD and designee .

Additional alignment policies:

  • Director stock ownership guidelines: Non-employee directors should hold shares equal to 3x annual cash fees; measured within five years. (Ms. Young receives no cash fees; guideline framework disclosed but individual compliance not specified) .
  • Anti-hedging/pledging: Hedging and pledging of CCC securities prohibited without pre-approval; applies to directors .

Governance Assessment

  • Advent influence and independence: Ms. Young is independent under Nasdaq/SEC rules yet is an Advent-appointed director with no personal CCCS share ownership; alignment is primarily through Advent’s significant equity stake rather than personal holdings .
  • Compensation and incentives: Ms. Young receives no CCC director cash or equity—reducing potential cash/equity conflicts but also limiting direct “skin-in-the-game” at the individual level (contrasted with CCC’s general director RSU program) .
  • Committee composition and oversight: Ms. Young serves on NCGC alongside Advent designees; Advent has rights to committee representation, including at least one director on each committee while above thresholds—heightening shareholder influence considerations but within disclosed governance arrangements .
  • Related-party safeguards: 2025 share repurchase from Advent was reviewed and approved by CCC’s independent Audit Committee, indicating process controls for transactions with the principal shareholder .
  • Attendance and engagement: Board/committee cadence was robust in 2024; directors (including Ms. Young) met or exceeded the 75% attendance threshold .
  • Shareholder sentiment: 2024 say-on-pay passed with ~68% support, suggesting moderate investor scrutiny of pay practices and governance (a broader signal for the Board) .

RED FLAGS and Watch Items:

  • Advent control features: Board/committee designation rights and a presiding director from Advent concentrate influence; monitor for potential conflicts in nominations/succession and ESG oversight .
  • Zero personal ownership: Ms. Young reports no direct CCCS holdings; while policy allows for Advent-affiliated directors to forgo compensation, individual ownership alignment is limited (offset by Advent’s 14.77% stake) .
  • Related-party activity: Ongoing capital markets transactions with Advent (e.g., repurchases) require continued independent committee oversight to mitigate conflicts .